Is Wegovy or Mounjaro Better for Inflammation? What the Evidence Actually Shows

The misconception: one of these medicines specifically 'targets' inflammation

A common belief is that Wegovy or Mounjaro work on inflammation as a distinct mechanism, rather like an anti-inflammatory drug. The reality is more nuanced. Both medicines reduce circulating levels of markers such as CRP (C-reactive protein) and certain interleukins in people with obesity — but the bulk of current evidence suggests this happens largely because significant weight loss itself damps down the low-grade chronic inflammation that excess adipose tissue drives. Obesity is associated with a persistently activated inflammatory state, and shedding a meaningful percentage of body weight tends to quieten it.

Researchers are actively studying whether GLP-1 and GIP receptor activation have direct anti-inflammatory effects independent of weight loss. Early trial data and mechanistic studies are interesting, but they have not yet translated into licensed indications. The NHS tirzepatide medicines page and the NHS semaglutide medicines page both describe the weight-management indication accurately, inflammation is not listed as a target condition.

So if you are reading about these medicines specifically because of an inflammatory condition, the honest starting point is this: the anti-inflammatory signal in the trials is real, but it is a secondary observation, not the primary purpose. Worth knowing before weighing the two up.

What the trials actually recorded, and where they differ

The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the 15mg tirzepatide dose over 72 weeks. The STEP 1 trial found semaglutide 2.4mg produced around 15% average reduction over 68 weeks, in a comparable population without diabetes. Both trials recorded reductions in CRP and other inflammatory biomarkers alongside weight loss, broadly proportional to the weight lost.

In the SURMOUNT-5 head-to-head trial (72 weeks, published in the New England Journal of Medicine, 2025), tirzepatide produced greater average weight loss than semaglutide 2.4mg in adults with obesity who did not have diabetes. Since the inflammatory improvement appears to track closely with weight loss magnitude, tirzepatide's larger average reduction would be expected to carry a correspondingly larger anti-inflammatory signal, but that is an inference, not a direct measured comparison of inflammation outcomes between the two drugs.

NICE's appraisal of tirzepatide (TA1026) and its earlier appraisal of semaglutide (TA875) both focus on weight-related comorbidities rather than inflammation specifically. Neither NICE document positions either medicine as an anti-inflammatory treatment. That matters for managing expectations.

A factual side-by-side: key points relevant to inflammation

The table makes the picture clearer. Tirzepatide produces larger average weight loss; if inflammation is your concern, that difference may matter. But it is a population average from a trial, not a personal prediction. The full evidence comparison goes into additional factors worth considering alongside this.

Which one is right for you depends on your whole clinical picture

Weight-related inflammation rarely exists in isolation. Many people asking this question are managing conditions like non-alcoholic fatty liver disease, osteoarthritis, polycystic ovary syndrome, or cardiovascular risk alongside excess weight, all of which have inflammatory components. Your prescriber needs to know the full picture before recommending one medicine over the other.

Practical differences matter too. Mounjaro is a once-weekly injection that goes into the fridge, most people keep it on the top shelf next to other chilled items and it becomes unremarkable within a week. Wegovy is also once-weekly and refrigerated. Oral semaglutide (Wegovy tablets) offers an injection-free route, though the trial weight-loss results are lower than the injections at this stage. If oral administration is important to you, our treatment overview covers all three options in one place.

Eligibility for each medicine is assessed individually. The licensed BMI thresholds are the same starting point (adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition) but your full medical history, current medications and the clinical judgement of a prescriber all shape the final decision. For a broader look at which is better, Mounjaro or Wegovy, including efficacy, tolerability and access, the Wegovy vs Mounjaro comparison covers these in more depth. Cost is another practical factor; UK pricing differences are worth understanding before you start. Neither medicine should be obtained without a valid prescription, the MHRA has warned repeatedly about counterfeit pens sold online, some of which have contained insulin rather than the stated medicine.

The clinical decision is made with you, not for you. If you are still weighing up what's better, Mounjaro or Wegovy, for your specific circumstances, including how the inflammatory evidence applies to you personally, a prescriber can help you work through that during a consultation. Separately, if you want a focused look at whether Mounjaro is better than Wegovy on the key outcome measures, that page sets out the trial data side by side. Start your free consultation and a prescriber at our GPhC-registered pharmacy will assess which treatment, if any, is appropriate for your situation. You can verify our registration at GPhC premises number 9012878.